These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 10914699

  • 1. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans.
    van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G, Sparreboom A.
    Clin Cancer Res; 2000 Jul; 6(7):2598-603. PubMed ID: 10914699
    [Abstract] [Full Text] [Related]

  • 2. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.
    van Zuylen L, Sparreboom A, van der Gaast A, van der Burg ME, van Beurden V, Bol CJ, Woestenborghs R, Palmer PA, Verweij J.
    Clin Cancer Res; 2000 Apr; 6(4):1365-71. PubMed ID: 10778964
    [Abstract] [Full Text] [Related]

  • 3. Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.
    van Zuylen L, Sparreboom A, van der Gaast A, Nooter K, Eskens FA, Brouwer E, Bol CJ, de Vries R, Palmer PA, Verweij J.
    Eur J Cancer; 2002 May; 38(8):1090-9. PubMed ID: 12008197
    [Abstract] [Full Text] [Related]

  • 4. Influence of ketoconazole on the fecal and urinary disposition of docetaxel.
    Engels FK, Loos WJ, Mathot RA, van Schaik RH, Verweij J.
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):569-79. PubMed ID: 17256132
    [Abstract] [Full Text] [Related]

  • 5. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans.
    Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R.
    Cancer Res; 1996 Mar 15; 56(6):1296-302. PubMed ID: 8640817
    [Abstract] [Full Text] [Related]

  • 6. MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models.
    Naito M, Matsuba Y, Sato S, Hirata H, Tsuruo T.
    Clin Cancer Res; 2002 Feb 15; 8(2):582-8. PubMed ID: 11839680
    [Abstract] [Full Text] [Related]

  • 7. P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing.
    Gustafson DL, Long ME, Bradshaw EL, Merz AL, Kerzic PJ.
    Cancer Chemother Pharmacol; 2005 Sep 15; 56(3):248-54. PubMed ID: 15856231
    [Abstract] [Full Text] [Related]

  • 8. Biotransformation of taxoids by human cytochromes P450: structure-activity relationship.
    Monsarrat B, Royer I, Wright M, Cresteil T.
    Bull Cancer; 1997 Feb 15; 84(2):125-33. PubMed ID: 9180834
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics and metabolism of Taxotere (docetaxel).
    Bruno R, Sanderink GJ.
    Cancer Surv; 1993 Feb 15; 17():305-13. PubMed ID: 7907950
    [Abstract] [Full Text] [Related]

  • 10. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.
    Bardelmeijer HA, Ouwehand M, Buckle T, Huisman MT, Schellens JH, Beijnen JH, van Tellingen O.
    Cancer Res; 2002 Nov 01; 62(21):6158-64. PubMed ID: 12414642
    [Abstract] [Full Text] [Related]

  • 11. Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay.
    Gustafson DL, Long ME, Zirrolli JA, Duncan MW, Holden SN, Pierson AS, Eckhardt SG.
    Cancer Chemother Pharmacol; 2003 Aug 01; 52(2):159-66. PubMed ID: 12759775
    [Abstract] [Full Text] [Related]

  • 12. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ, Lagas JS, Rosing H, Schellens JH, Beijnen JH, Schinkel AH.
    Int J Cancer; 2013 May 15; 132(10):2439-47. PubMed ID: 23090875
    [Abstract] [Full Text] [Related]

  • 13. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity.
    van Waterschoot RA, Lagas JS, Wagenaar E, van der Kruijssen CM, van Herwaarden AE, Song JY, Rooswinkel RW, van Tellingen O, Rosing H, Beijnen JH, Schinkel AH.
    Cancer Res; 2009 Dec 01; 69(23):8996-9002. PubMed ID: 19920203
    [Abstract] [Full Text] [Related]

  • 14. Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.
    Loos WJ, Baker SD, Verweij J, Boonstra JG, Sparreboom A.
    Clin Pharmacol Ther; 2003 Oct 01; 74(4):364-71. PubMed ID: 14534523
    [Abstract] [Full Text] [Related]

  • 15. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.
    Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH.
    Clin Cancer Res; 2000 Apr 01; 6(4):1255-8. PubMed ID: 10778948
    [Abstract] [Full Text] [Related]

  • 16. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093).
    Kuppens IE, Bosch TM, van Maanen MJ, Rosing H, Fitzpatrick A, Beijnen JH, Schellens JH.
    Cancer Chemother Pharmacol; 2005 Jan 01; 55(1):72-8. PubMed ID: 15316750
    [Abstract] [Full Text] [Related]

  • 17. Clinical pharmacokinetics of docetaxel.
    Clarke SJ, Rivory LP.
    Clin Pharmacokinet; 1999 Feb 01; 36(2):99-114. PubMed ID: 10092957
    [Abstract] [Full Text] [Related]

  • 18. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.
    Nygren P, Hande K, Petty KJ, Fedgchin M, van Dyck K, Majumdar A, Panebianco D, de Smet M, Ahmed T, Murphy MG, Gottesdiener KM, Cocquyt V, van Belle S.
    Cancer Chemother Pharmacol; 2005 Jun 01; 55(6):609-16. PubMed ID: 15723220
    [Abstract] [Full Text] [Related]

  • 19. The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice.
    Press RR, Buckle T, Beijnen JH, van Tellingen O.
    Cancer Chemother Pharmacol; 2006 Jun 01; 57(6):819-25. PubMed ID: 16163538
    [Abstract] [Full Text] [Related]

  • 20. Interaction of docetaxel ("Taxotere") with human P-glycoprotein.
    Shirakawa K, Takara K, Tanigawara Y, Aoyama N, Kasuga M, Komada F, Sakaeda T, Okumura K.
    Jpn J Cancer Res; 1999 Dec 01; 90(12):1380-6. PubMed ID: 10665657
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.